Medicines for Familial Mediterranean fever

What it is

Familial Mediterranean fever (FMF) is an inherited (genetic) autoinflammatory condition that causes recurring attacks of fever and inflammation. It is most common in people of certain ancestries around the Mediterranean and Middle East (such as those of Turkish, Armenian, Arab, and Sephardic Jewish descent), reflecting its genetic basis. During an attack, which typically lasts one to three days and then settles, there is fever together with inflammation of one or more areas — most commonly the lining of the tummy (causing severe abdominal pain that can mimic appendicitis), the lining of the chest (causing chest pain), the joints (causing pain and swelling), and sometimes a skin rash. Attacks come on unpredictably, with the person usually well in between, and often begin in childhood or early adulthood. As well as the attacks themselves being painful and disruptive, an important long-term concern with untreated FMF is a risk of a serious complication called amyloidosis, where a protein builds up in organs (particularly the kidneys) and can damage them over time. This is a key reason that regular preventive treatment is important. FMF is diagnosed from the pattern of attacks, ancestry, and genetic testing, and is managed by specialists.

How it is treated

The cornerstone of managing familial Mediterranean fever is a regular daily medicine called colchicine, which is highly effective and central to treatment. Taken continuously (not just during attacks), colchicine both greatly reduces the frequency and severity of the attacks in most people and — crucially — reduces the risk of the long-term complication amyloidosis, which is the main threat to long-term health. So the key message for people with FMF is the importance of taking colchicine regularly and long-term, as prescribed, even when feeling well between attacks, and it is generally well tolerated with monitoring. For attacks themselves, supportive measures and pain relief help while they settle. For the minority of people who do not respond adequately to colchicine or cannot tolerate it, other treatments — including targeted biologic medicines that block specific inflammatory signals — are effective and used under specialist care. Regular monitoring (including checking the kidneys and for signs of amyloidosis) is an important part of long-term care. Genetic counselling and family testing may be offered, given the inherited nature. The reassuring message is that familial Mediterranean fever is very treatable — regular colchicine controls the attacks and protects against the serious long-term complication — and that specialist care and monitoring keep the condition well managed.